Global tuberculosis drug development pipeline: the need and the reality
- 19 May 2010
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 375 (9731), 2100-2109
- https://doi.org/10.1016/s0140-6736(10)60359-9
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practiceThe Lancet, 2010
- New vaccines for tuberculosisThe Lancet, 2010
- Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnosticsProceedings of the National Academy of Sciences of the United States of America, 2009
- Long term efficacy of DOTS regimens for tuberculosis: systematic reviewBMJ, 2008
- Treatment Outcomes of Patients with HIV and TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Association between Acquired Rifamycin Resistance and the Pharmacokinetics of Rifabutin and Isoniazid among Patients with HIV and TuberculosisClinical Infectious Diseases, 2005
- Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Interactions among Drugs for HIV and Opportunistic InfectionsThe New England Journal of Medicine, 2001
- The action of antituberculosis drugs in short-course chemotherapyTubercle, 1985
- Studies in Short-Course Chemotherapy for TuberculosisSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1981